ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0376

Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry

Gaelle Chedeville1, Heinrike Schmeling2, Jean-Philippe Proulx-Gauthier3, Michelle Batthish4, Jean Jacques De Bruycker5, Brian Feldman6, Roberta A Berard7, Roxana Bolaria8, Amieleena Chhabra9, Lily Lim10, Adam Huber11, Matthew Berkowitz12, Thomas Loughin12 and Jaime Guzman13, and CAPRI Registry Investigators, 1The Montreal Children's Hospital, Montreal, QC, Canada, 2University of Calgary, Calgary, AB, Canada, 3CHU de Quebec - Universite Laval, Quebec, QC, Canada, 4McMaster Children's Hospital, Hamilton, ON, Canada, 5UNIVERSITY OF MONTREAL, Montreal, QC, Montreal, QC, Canada, 6Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 7London Health Sciences Centre, London, ON, Canada, 8Victoria Arthritis Center, Victoria, BC, Canada, 9University of British Columbia, Penticton, BC, Canada, 10University of Manitoba, Winnipeg, MB, Canada, 11IWK Health Centre, Halifax, NS, Canada, 12Simon Fraser University, Burnaby, BC, Canada, 13University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada

Meeting: ACR Convergence 2024

Keywords: clinical trial, Drug toxicity, Juvenile idiopathic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: About 50% of children with Juvenile Idiopathic Arthritis (JIA) receiving methotrexate (MTX) develop MTX intolerance with severe anticipatory nausea/vomiting and avoidance behaviors. Intolerance often leads to poor adherence or stopping MTX. Our aim was to evaluate if routine premedication with the anti-emetic ondansetron reduces MTX intolerance and increases the proportion of children able to continue MTX, compared to as-needed ondansetron use.

Methods: Children 4-16 years in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry who were starting MTX for the first time were assigned, via stratified block randomization by Canadian region and patient weight, to: 1) routine premedication with oral ondansetron from the very first dose of MTX (intervention), or 2) ondansetron used only after developing nausea/vomiting (control). Ondansetron was prescribed as 3 doses weekly starting one hour before MTX (2mg if < 15Kg, 4 mg if 15-30 Kg, or 8mg if >30Kg). The primary endpoint was the proportion of children who remain on MTX with good tolerance one year after starting MTX. We hypothesized this would happen in ≥75% intervention patients versus 50% in control patients. Intolerance was ≥6 points in the MTX Intolerance Severity Score. The COVID19 pandemic slowed recruitment and the planned interim analysis was conducted with patients recruited as of October 6, 2023. Any patient who developed intolerance or discontinued MTX within a year of starting it was considered a failure, and one-year success rates were estimated with Kaplan Meier survival analysis.

Results: Sixty-one children were assessed for eligibility, 52 were randomized and 44 contributed to the Kaplan Meier analysis. Participants randomized to intervention (n=22) or control (n=30) had comparable baseline characteristics, despite the imbalance in number of participants due to use of stratified blocks. After a median follow-up of 45.5 weeks (intervention) and 39 weeks (controls), we observed 7 failures in the intervention group and 8 failures in the control group with 59% and 83% of participants still on MTX at last follow-up, respectively. The estimated success at one year was 57% for intervention and 59% for controls (risk ratio 0.91; 99% CI 0.39, 2.08).  Based on computer simulations, the probability of observing results like this if our a hypothesized success rates (75% and 50%, respectively) are correct is 0.055. Forty-six adverse events were reported (mostly gastrointestinal, 17 in intervention and 29 in control, respectively), and one was serious (infection with hospitalization in a patient not receiving ondansetron).

Conclusion: This interim analysis showed very little signal to suggest prophylactic ondansetron increases the proportion of patients remaining on MTX with no intolerance one year after starting it, relative to using ondansetron after nausea or vomiting develop. Based on these results, the Data and Safety Committee deemed enrolling additional patients was unlikely to change findings. It recommended stopping recruitment into the trial and completing follow-up of all subjects already enrolled.
NCT04169828.  Funded by The Arthritis Society, Canada.

Supporting image 1

Figure 1: Screening, randomization and follow-up of study participants

Supporting image 2

Table 1: Patient characteristics at baseline

Supporting image 3

Figure 2. Estimated proportion of patients remaining on methotrexate with good tolerance


Disclosures: G. Chedeville: None; H. Schmeling: AbbVie/Abbott, 5, Bristol-Myers Squibb(BMS), 5, Janssen, 5, Pfizer, 5, UCB, 5; J. Proulx-Gauthier: None; M. Batthish: Abbvie, 6, Novartis, 2, Viatris, 12, Unrestricted Educational Grant; J. De Bruycker: Novartis, 1; B. Feldman: None; R. Berard: AbbVie/Abbott, 1, Sandoz, 1; R. Bolaria: None; A. Chhabra: None; L. Lim: None; A. Huber: None; M. Berkowitz: None; T. Loughin: None; J. Guzman: None.

To cite this abstract in AMA style:

Chedeville G, Schmeling H, Proulx-Gauthier J, Batthish M, De Bruycker J, Feldman B, Berard R, Bolaria R, Chhabra A, Lim L, Huber A, Berkowitz M, Loughin T, Guzman J. Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/preliminary-results-of-the-ondansetron-pre-medication-trial-in-juvenile-idiopathic-arthritis-a-pragmatic-randomized-controlled-trial-nested-in-the-capri-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preliminary-results-of-the-ondansetron-pre-medication-trial-in-juvenile-idiopathic-arthritis-a-pragmatic-randomized-controlled-trial-nested-in-the-capri-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology